PRPH (ProPhase Labs) Stock Based Compensation: $1.76 Mil (TTM As of Mar. 2026)


What is ProPhase Labs Stock Based Compensation?

ProPhase Labs PRPH -13.04% Stock Based Compensation is $1.76 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

ProPhase Labs's Stock Based Compensation for the three months ended in Mar. 2026 was $0.39 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $1.76 Mil.

ProPhase Labs Stock Based Compensation Related Terms

ProPhase Labs Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for ProPhase Labs's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProPhase Labs Stock Based Compensation Chart

ProPhase Labs Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.18 3.99 3.54 3.64 1.89

ProPhase Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.51 -1.03 1.89 0.39

ProPhase Labs Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.76 Mil.

What does a Stock Based Compensation of $1.76 Mil mean?
ProPhase Labs (PRPH) has a Stock Based Compensation of $1.76 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for ProPhase Labs and its competitors.
Is ProPhase Labs' Stock Based Compensation too high?
ProPhase Labs' current Stock Based Compensation is $1.76 Mil.
How does ProPhase Labs' Stock Based Compensation compare to IDTA and IVRO?
ProPhase Labs' Stock Based Compensation of $1.76 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Diagnostics & Research company?
A good Stock Based Compensation depends on the Medical Diagnostics & Research industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for ProPhase Labs and its competitors. ProPhase Labs's current Stock Based Compensation is $1.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.85, compared to a current price of $0.08 — trading 90.6% below its estimated fair value. The current Stock Based Compensation is $1.76 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Stock Based Compensation is $1.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProPhase Labs Business Description

Address 626 RXR Plaza, 6th Floor, Uniondale, NY, USA, 11556
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.